Shire Pharmaceuticals Group Plc
Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
Zug, Switzerland (ots/PRNewswire) - - Cuvitru (IG 20mg/ml solution for subcutaneous injection) builds on company's broad portfolio of IG treatments gained through combination with Baxalta - New option to treat primary and certain secondary immunodeficiencies can help meet patient needs related to number of infusion ...